| 37.1 2.54 (7.35%) | 04-22 15:56 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 47.45 | 1-year : | 52.85 |
| Resists | First : | 40.63 | Second : | 45.25 |
| Pivot price | 37.66  |
|||
| Supports | First : | 33.15 | Second : | 27.58 |
| MAs | MA(5) : | 37.28 |
MA(20) : | 38.61 |
| MA(100) : | 44.88 |
MA(250) : | 45.18 |
|
| MACD | MACD : | -1.3 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 36.6 |
D(3) : | 42.7 |
| RSI | RSI(14): 45.4 |
|||
| 52-week | High : | 60.9 | Low : | 29.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TWST ] has closed above bottom band by 41.5%. Bollinger Bands are 38.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 36.29 - 36.54 | 36.54 - 36.74 |
| Low: | 33.12 - 33.44 | 33.44 - 33.7 |
| Close: | 34.1 - 34.55 | 34.55 - 34.9 |
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
Mon, 14 Apr 2025
Earnings Alert: Twist Bioscience Sets Key Q2 Financial Results Date - What to Watch - Stock Titan
Mon, 14 Apr 2025
Twist Bioscience to Report Fiscal 2025 Second Quarter Financial Results on Monday, May 5, 2025 - Business Wire
Mon, 31 Mar 2025
Twist Bioscience and Curio Genomics Collaborate to Accelerate and Streamline NGS Adoption in Agrigenomics - Business Wire
Thu, 20 Mar 2025
Twist Bioscience (TWST): The Worst High-Risk High-Reward Growth Stock to Buy - Yahoo Finance
Tue, 11 Mar 2025
Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost - Business Wire
Tue, 11 Mar 2025
Academic Breakthrough: Twist Bioscience Now Offers 4-Day Gene Synthesis at Zero Extra Cost - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 60 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 112.3 (%) |
| Shares Short | 8,830 (K) |
| Shares Short P.Month | 9,220 (K) |
| EPS | -3.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.65 |
| Profit Margin | -59.8 % |
| Operating Margin | -39.1 % |
| Return on Assets (ttm) | -15.3 % |
| Return on Equity (ttm) | -37.8 % |
| Qtrly Rev. Growth | 24.1 % |
| Gross Profit (p.s.) | 2.46 |
| Sales Per Share | 5.53 |
| EBITDA (p.s.) | -2.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -63 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -10.99 |
| PEG Ratio | 0 |
| Price to Book value | 4.85 |
| Price to Sales | 6.7 |
| Price to Cash Flow | -35.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|